logo
Plus   Neg
Share
Email

EBay Issues Business Outlook - Quick Facts

eBay Inc. (EBAY) said, for the second quarter 2020, the company expects non-GAAP earnings per share from continuing operations in the range of $0.73 - $0.80, and net revenue between $2.38 billion and $2.48 billion, representing organic FX-neutral growth of 2% - 6%.

Given the dynamic environment, the company has decided not to revise its full year revenue and earnings per share estimates. For 2020, the company expects non-GAAP earnings per share from continuing operations in the range of $3.00 - $3.10, and net revenue between $9.56 billion and $9.76 billion, representing organic FX-neutral growth of 1% - 3%.

First quarter non GAAP earnings per share from continuing operations was $0.77 compared to $0.65, previous year. On average, 31 analysts polled by Thomson Reuters expected the company to report profit per share of $0.72, for the quarter. Analysts' estimates typically exclude special items.

First quarter revenue was $2.4 billion, down 2% on an as-reported basis and up 1% on a foreign exchange neutral basis. Active buyers grew by 2%, for a total of 174 million global active buyers. Analysts expected revenue of $2.38 billion for the quarter.

eBay's Board has declared a cash dividend of $0.16 per share of the company's common stock. The dividend is payable on June 19, 2020 to stockholders of record as of June 1, 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Elon Musk, chief executive of electric car maker Tesla, said its own battery cells, which are under development now, will not reach high-volume production until 2022. This delay can affect the Cybertruck, Semi, and Roadster programs. He also said the company intends to increase battery cell purchases from partners Panasonic, LG & CATL, and possibly other partners. U.S. Court grants Tiffany's motion to expedite lawsuit against LVMH Moët Hennessy-Louis Vuitton. However, the court has not agreed to Tiffany request for trial before November 24. Biotech company Illumina agreed to buy healthcare company GRAIL, Inc. in a cash and stock deal valued at $8 billion. This includes $3.5 billion in cash and $4.5 billion in shares of Illumina common stock. GRAIL focuses on multi-cancer early detection from blood. It is in the process of developing the technology and providing clinical data required to launch the Galleri multi-cancer screening test.
Follow RTT